No headlines found.
Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds
Globe Newswire (Fri, 1-Mar 7:00 PM ET)
Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office
Globe Newswire (Wed, 28-Feb 9:30 AM ET)
Adial Pharmaceuticals to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20
ACCESSWIRE (Thu, 15-Feb 9:02 AM ET)
Globe Newswire (Tue, 13-Feb 9:15 AM ET)
Adial Announces Appointment of Tony Goodman as Chief Operating Officer
Globe Newswire (Thu, 18-Jan 8:30 AM ET)
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder.
Adial Pharmaceuticals trades on the NASDAQ stock market under the symbol ADIL.
As of March 28, 2024, ADIL stock price declined to $1.33 with 73,322 million shares trading.
ADIL has a beta of 3.76, meaning it tends to be more sensitive to market movements. ADIL has a correlation of 0.07 to the broad based SPY ETF.
ADIL has a market cap of $1.62 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, ADIL stock traded as high as $127.00 and as low as $.77.
The top ETF exchange traded funds that ADIL belongs to (by Net Assets): VXF.
ADIL has underperformed the market in the last year with a price return of -86.0% while the SPY ETF gained +33.6%. ADIL has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -26.9% and -24.0%, respectively, while the SPY returned +10.1% and +1.7%, respectively.
ADIL support price is $1.19 and resistance is $1.61 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ADIL stock will trade within this expected range on the day.